Charly Chahwan

Company: SyntheX

Job title: Chief Scientific Officer

Seminars:

Disruption of the RAS-RAF1 Interaction: A New Synthetic Lethality Strategy for Selectively Blocking RAS-Driven Proliferation of Cancer Cells 5:00 pm

Using our PPI-disruption identifying platform, ToRPPIDO, we have discovered several new compounds that allosterically disrupt the Ras-Raf1 protein-protein interaction by binding Raf1 in a new pocket distal to its Ras Binding Domain STX200, a cell-permeable member of this set, exhibits a potent anti-proliferative activity against a variety of mutant RAS cancer lines The anti-proliferative activity…Read more

day: Day One Track G

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.